Search Results for "VEGF inhibitors"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for VEGF inhibitors. Results 1 to 5 of 5 total matches.
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet) age related
macular ...
The FDA has approved Susvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet) age-related
macular degeneration (nAMD) in patients who
have previously responded to at least two intravitreal
injections of a VEGF inhibitor. Ranibizumab intravitreal
injection (Lucentis) has been available since 2006 for
monthly treatment of nAMD. The FDA has approved
ranibizumab-nuna (Byooviz), a biosimilar of Lucentis
and the first ophthalmologic biosimilar; it will be
available in June...
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
beyond
2 years of treatment is unclear.
▶ Treatment of wet AMD with VEGF inhibitors has reduced vision ...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 doi:10.58347/tml.2025.1719a | Show Introduction Hide Introduction
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
with
vascular endothelial growth factor (VEGF) inhibitors
has reduced vision loss in wet AMD.2
MECHANISM ...
The FDA has approved the complement C3 inhibitor
pegcetacoplan (Syfovre – Apellis) for treatment of
geographic atrophy (GA) secondary to age-related
macular degeneration (AMD). Given as a series of
monthly or every-other-month (EOM) intravitreal
injections, it is the first drug to become available for
use in patients with atrophic dry AMD. Subcutaneous
pegcetacoplan was approved earlier as Empaveli for
treatment of paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):49-50 doi:10.58347/tml.2023.1673a | Show Introduction Hide Introduction
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
into the subretinal space. Vascular endothelial
growth factor (VEGF) inhibitors can markedly reduce
vision loss ...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 doi:10.58347/tml.2024.1694d | Show Introduction Hide Introduction